XNAS · Healthcare · Biotechnology
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.47 | -0.43 | +8.51% | $18.7M | ✅ Beat | -7.39% | -16.78% | — |
| 2026-03-04 | Q4 2025 | -0.49 | -0.48 | +2.04% | $17.5M | ✅ Beat | +2.41% | +6.54% | -3.10% |
| 2025-11-04 |
| Q3 2025 |
| -0.57 |
| -0.54 |
| +5.26% |
| $11.2M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-20 | Q4 2024 | -0.81 | -0.60 | +25.93% | $0 | ✅ Beat | -2.49% | -1.32% | -8.94% |
| 2024-03-14 | Q4 2023 | -0.62 | -1.10 | -77.42% | $0 | ❌ Miss | — | — | — |
| 2023-11-08 | Q3 2023 | -0.84 | -0.71 | +15.48% | $0 | ✅ Beat | -5.66% | -13.15% | +4.10% |
| 2023-08-08 | Q2 2023 | -1.07 | -1.06 | +0.93% | $0 | ✅ Beat | -0.30% | -4.79% | -1.99% |
| 2023-05-09 | Q1 2023 | -0.96 | -1.08 | -12.50% | $0 | ❌ Miss | -0.93% | -1.63% | +116.28% |
Showing last 8 quarters.